Back to results
US 2004/0082604 A1Published application
Thiazole and imidazo (4,5-B) pyridine compounds and their pharmaceutical use
AssigneeNovartis AG
InventorLaszlo Revesz
Life of this patent
Estimating the term…
Abstract
Compounds of formula (I) 1 and pharmaceutically-acceptable and pharmaceutically-acceptable and -cleavable esters thereof and acid addition salts thereof, wherein the symbols are as defined are MAP kinase inhibitors, useful pharmaceutically for treating TNFα and IL-1 mediated diseases such as rheumatoid arthritis and diseases of bone metabolism, e.g. osteoporosis.
Claims13
A compound of formula I
- 83
- wherein Nu is a heterocyclic nucleus selected from thiazole in which the R1, R2 and R3 substituents are disposed as indicated below
- 84
- or imidazo[4,5-b]pyridine in which the R1, R2 and R3 substituents are disposed as indicated below
- 85
- wherein
- R1 is pyrimidyl or pyridyl;
- X is —NR6—Y—, —O— or —S—,
- where R6 is H, C1-C4alkyl, C3-C8cycloalkyl, C3-C8cycloalkylC1C3alkyl, C6-C18aryl, C3-C18heteroaryl, C7-C19aralkyl or C4-C19heteroaralkyl, and —Y— is C1-C4alkylene or a direct bond;
- R2 is phenyl, optionally substituted by one or more substituents, each of which is independently selected from
- halo,
- CF3,
- cyano,
- amido or thioamido which is optionally mono- or di-N-substituted by C1-C4alkyl or the N atom of which forms a 5-7 membered heterocyclic ring optionally containing an additional hetero atom selected from O, S or N which N is optionally C—C4alkyl C1-C4alkylcarbonyl or C1-C4alkylthiocarbonyl substitued,
- carboxylate or thiocarboxylate optionally in the form of an optionally halo-substituted C1-C10alkoxy, C2-C10alkenoxy, C2-C10alkynoxy, C3-C7cyclalkoxy, C5-C7cycloalkenoxy, aryloxy, arylalkoxy, heteroaryloxy or heteroarylalkoxy ester,
- optionally mono- or di-C1-C4alkyl-substituted-C0-C1alkyl optionally C1-C4alkyl- or C3-C5 cycloalkyl-substituted-carbonyl or -thiocarbonyl,
- optionally halo-substituted-C1-C4alkoxy, C2-C4alkenoxy, C2C4alkynoxy, C3-C5cycloalkoxy or C3-C5cyclothioalkoxy,
- optionally halo substituted C1-C4 alkyl,
- oxycarbonyl or optionally N—C1-C4alkyl-substituted aminocarbonyl both of which are optionally C1-C4alkyl or C3-C5cycloalkyl substituted (including thiocarbonyl analogues thereof),
- optionally mono- or di-C1-C4alkyl-substituted-C0C1alkylamine which is optionally mono-or di-N—C1-C4 alkyl substituted,
- optionally mono- or di-C1-C4alkyl-substituted-C0-C1alkyl optionally N—C1-C4alkyl-substituted amino-carbonyl or -thiocarbonyl,
- optionally N—C1-C4alkyl-substituted amino-sulphinyl or -sulphonyl optionally substituted by
- optionally mono- or di-N—C1-C4alkyl-substituted amino,
- a nitrogen atom which form a heterocyclic ring of 5 to 7 members optionally containing an additional heteroatom selected from O, S or N which N is optionally C1-C4alkyl C1-C4alkylcarbonyl or C1-C4alkylthiocarbonyl substitued, or
- sulphinyl or sulphonyl optionally substituted by
- optionally halo-substituted-C1-C4alkyl, C2-C4 alkenyl, C2-C4 alkynyl,
- optionally mono- or di-C1-C4alkyl-substituted amino,
- a nitrogen atom which form a heterocyclic ring of 5 to 7 members optionally containing an additional heteroatom selected from O, S or N which N is optionally C1-C4alkyl C1-C4alkylcarbonyl or C1-C4alkylthiocarbonyl substitued;
- R3 is H, amino, C1-C10alkyl, C3-C10cycloalkyl, C3-C18heterocycloalkyl, C6-C18aryl, or C3-C18heteroaryl each of which is optionally substituted by up to 4 substituents separately selected from C1-C4alkyl, halogen, halo-substitued-C1-C4alkyl, hydroxy, C1-C4alkoxy, C1-C4alkylthio, C6-C18aryl, C3-C18heteroaryl, C6-C18arylC1-C4alkyl, C3-C18 heteroarylC1-C4alkyl, C3-C18heterocycloalkyl or optionally mono- or di-C1-C4alkyl substituted amino or by N-heterocyclyl containing from 5 to 7 ring atoms and optionally a further hetero atom selected from O, S or N, all of which are further optionally substituted halo, hydroxy, C1-C4alkyl, C1-C4alkoxy or C1-C4alkoxycarbonyl;
- R4 is C1-C10alkyl, C6-C18aryl C3-C18heteroaryl, or C3-C12cycloalkyl optionally substituted by up to 3 substituents separately selected from C1-C4alkyl, halogen, halo-substitued- C1-C4alkyl hydroxy, C1-C4alkoxy, C1-C4alkylthio, optionally mono- or di-C1-C4alkyl substituted amino, or by N-heterocyclyl containing from 5 to 7 ring atoms and optionally containing a further hetero atom selected from O, S or N,
- and pharmaceutically-acceptable and -cleavable esters thereof and acid addition salts thereof
28 more elements
A process for the production of
- (i) an Agent of the Invention of formula V″
- 92
- wherein R11, R12, R14 and X are as previously defined and R13″ is —CH2—CH2NR15R16 or —CH2—CH2-Het wherein R15, R16 and Het are as previously defined comprising reacting a corresponding vinyl precursor of formula VI
- 93
- wherein R11, R12, R14 and X are as previously defined with the corresponding amine of formula HNR15R16, or N-heterocycloalkyl ring compound;
- (ii) an Agent of the Invention of formula V wherein R13 is aryl or heteroaryl comprising arylation or heteroarylation of a compound of formula VII
- 94
- wherein R11, R12, R14 and X are as previously defined;
- (iii) an Agent of the Invention of formula V wherein R13 is —N-heterocycloalkyl, —NH-aryl, —NH—heteroaryl, —NH-heterocycloalkyl, —NH—(C1-C4alkyl)-heterocycloalkyl, —NH—(C1-C4alkyl)-aryl, —NH—(C1-C4alkyl)-heteroaryl, or —NH—(C1-4alkyl)-heterocycloalkyl comprising coupling a corresponding chloroprecursor compound of formula VII, as defined above, with the corresponding N-heterocycloalkyl compound or amine;
- (iv) an Agent of the Invention of formula V in which R13 is —NH2, comprising reacting the corresponding methyl sulphinyl compound of formula VIII′
- 95
- wherein R11, and R12 are as previously defined, with the corresponding amine of formula R14—NH2, and
- (v) an Agent of the Invention of formula V in which R13 is piperazinyl, comprising reacting a corresponding methylsulphinyl compound of formula VIII′
- 96
- wherein R1, and R12 are as previously defined and P is an N protecting group, with the corresponding amine of formula R14—NH2.
12 more elements
Dependencies are inferred from the claim text.